Wi Kɔmni
       Pɛptayd dɛn        Janoshik COA
Yu de ya: Os » Pɛptida Risach » Pɛptida Risach » Kadiɔjen: Aplikeshɔn fɔ Kadiɔvaskyuɛl Ɛlth Mentɛnans

Kadiɔjen: Aplikeshɔn insay Kadiɔvaskyuɛl Ɛlth Mentɛnans

netwok_duotone Na Cocer Peptides bin rayt am      netwok_duotone 31 dez bifo


ƆL DI ATIKUL ƐN PRODƆKT INFƆMƐSHƆN WE DƐN GI NA DIS WƐBSAYT NA FƆ ƆL FƆ DI INFƆMƐSHƆN ƐN FƆ EDYUKESHƆN.  

Di prɔdak dɛn we dɛn gi na dis wɛbsayt na fɔ in vitro risach nɔmɔ. in vitro risach (Latin: *in glas*, we min insay glas) dεn de du am ausayd mכtalman bכdi. Dɛn prɔdak ya nɔto mɛrɛsin, dɛn nɔ gɛt di aprɔval frɔm di US Food and Drug Administration (FDA), ɛn dɛn nɔ fɔ yuz dɛn fɔ protɛkt, trit, ɔ mɛn ɛni mɛrɛsin, sik, ɔ sik. Di lɔ nɔ gri fɔ mek dɛn put dɛn tin ya insay mɔtalman ɔ animal bɔdi ɛni we.




Ovaviu fɔ di tin dɛn we dɛn dɔn lan


Kadiojen, na wan tin we gɛt bɔku intres pan di fild fɔ mek di at ɛn di blɔd gɛt wɛlbɔdi, gɛt sɔs ɛn di kayn we aw i rili impɔtant fɔ ɔndastand di wok we i de du fɔ mek di at ɛn di blɔd gɛt wɛlbɔdi. i de intarakt wit spεsifi k tכgεt dεm insay di kכdivaskyul sistεm, we de mek in hεlth-mεnten ifekt dεm pan di kכdivaskyul sistεm.

1

Figure 1. Epijenεtik mεkanism dεm na di kכdivaskyul dizכrd dεm. di hat (senta) de kכnekt to tri mεjכr epijεnik rεgεdyushכn mεkanism dεm we de infכlכp di kכdivaskyul pathophysiology.





Ifɛkt dɛn


Di tin dɛn we kin apin to di at

rεgulεshכn fכ di at rεt: di kadyכjen kin rεgεl di at in ritm prεsis, we de kip di at rεt insay di nכmal rεnj. כnda strεs kכndishכn, lεk we di bכdi de stimulate wit strεs כmon dεm lεk adrenaline, di at kin gεt takikardia. di kadyojen de kompens di strεs ifekt dεm we adrenaline de gi pan di at fayn fayn wan, i de εp fכ lכs di at rεt to nכmal kכntrכl valyu dεm we i de ridyus di כkכrεshכn fכ aritmia, so dat i de mεnten nכmal kadyak pכmp fכnshכn εn mek sכh se di bכdi de gi di כl bכdi fayn fayn wan.


fכ protεkt di mayokardia rigεnεreshכn: fכ fala di kadyak sik dεm lεk mayokardial infarkshכn, di mayokardial tisu dεm de pwεl. di kadyojen gεt imכtant rol fכ protεkt di mayokardial rigεnεreshכn bay we i de indyuz εndojεnik mεsenchymal stεm sεl dεm (MSC) fכ difrεnt to kadyomayosayt dεm, we de mek i de ripεr di mayokardial tisu dεm we dεn dכn pwεl. bay we i de mek di rilevεnt signal path dεm—di ki path dεm we de involv insay di εmbrayo hat indukshכn εn angiojεnεsis—i de protεkt di rigεnεreshכn εn proliferashכn fכ di kadyomayosayt dεm, we de mek di kadyak fכnshכn bכku εn i de mek di at in kכntrakt εn dayastolik kεpabiliti dεm bכku.


Di tin dɛn we kin apin to di blɔd vesel dɛn

fכ impruv di vaskulכr εndoteyl fכnshכn: di vaskul εndoteyl sεl dεm na implεnt fכ mεnten di nכmal fysiolojikal fכnshכn dεm fכ di bכdi vεsul dεm. di kadyojen de mek di vaskulכr εndoteyl sεl dεm hεlth εn i de mek dεn ebul fכ sekret vasodilatory sכbstans dεm lεk naytrik oksayd. Nitric oxide de rilaks di vaskul smol smol mכsul, dat de mek di bכdi vεsul dεm dilayt, i de ridyus di vaskulεr rεsistεns, i de mek di bכdi go bεtεh, εn i de lכs di risk fכ kכdivaskyul sik dεm.


fכ inhibit vaskulεr inflameshn: inflammatory rεspכns dεm de ple imכtant rol fכ divεlכpmεnt fכ vaskulεr sik dεm lεk atεrosklεrosis. di kadyojen kin sכpres di inflammatory rispכns dεm insay di vaskulכr wכl, we de ridyus di infiltεshכn fכ di inflammatory sεl dεm εn di rilis fכ inflammatory fכktכ dεm. bay we i de inhεbit inflammatory kaskad dεm, i de mek di vaskulכr wכl dεm we dεn dכn pwεl, i de εp fכ mεnten nכmal vaskulכr strכkchכ εn fכnshכn εn fכ mek di vaskulכr nכrכw εn blכk.




Aplikeshɔn dɛn


Mayokardial infarkshכn tritmεnt: Fכ di sik pipul dεm we gεt mayokardial infarkshכn, fכ intavεnshכn kwik wit Cardiogen afta di sik bigin kin mek di mayokardial rijenereshכn εn ripa, ridyus di infarkshכn εria, εn impruv di kadyak fכnshכn. Administreshɔn kin bi bay ɔral ɔ injɛkshɔn rod, wit spɛshal administreshɔn rod ɛn doz dɛn we dɛn kin ajɔst wan wan bay di pɔsin in kɔndishɔn ɛn in bɔdi stetmɛnt. Klinik stכdi dεn sho se di sik pipul dεm we gεt mayokardial infarkshכn we de gεt Cardiogen tritmεnt de sho bכku improvεmεnt dεm na di kadyak fכnshכn indikεtכ dεm lεk ejekshכn frakshכn, we de εnhans dεn kwaliti כf layf εn sכvayv rεt.


Tritmɛnt fɔ aritmia: Kadiojen kin rigul di at rit ɛn stebul di aritmia fɔ difrɛn kayn aritmia. Fɔ di wan dɛn we gɛt mild aritmia, tritmɛnt wit Cardiogen kin ridyus di frɛkuɛns ɛn di siriɔs aritmi episɔd, fɔ avɔyd ɔ ridyus di sayd ifɛkt dɛn we gɛt fɔ du wit tradishɔnal antiaritmi drɔgs. Insay klinik prɛktis, dɔktɔ dɛn go yuz Kadiɔjen fayn fayn wan bay di pɔsin in ilɛktrɔkadiogram monitarin rizɔlt ɛn di simptom manifestɔshɔn.




Risach we gɛt fɔ du wit dis


Animal Ekspirimɛnt Stɔdi: Bɔku animal ɛkspiriɛns dɔn du dip invɛstigeshɔn fɔ di Cardiogen in kadiovaskular protɛktiv ifɛkt dɛm. insay rat εkspεriεns, afta dεn establish wan mayokardial infarkshכn mכdel εn administret Kadiכjen intavεnshכn, dεn si signifyant mayokardial rijεneshכn na di mayokardial infarkshכn εria, wit kadyak fכnshכn indikεtכ dεm lεk lεft vεntrikul εjεkshכn frakshכn sכmtεm improv. apat frכm dat, insay vaskulεr-rεlatεd εkspεriεns, dεn bin si se Kadyכjen kin inhεbit vaskulεr εndoteyl proliferashכn εn ridyus di fכmeshכn כf atεrosklεrotik plek dεm, we sho se i gεt gud prכtektiv ifekt pan blכd vεsul dεm. dis animal εkspεriεns dεm de gi imכtant tiori fכwndeshכn dεm εn εkspεriεns pruf fכ di aplikεshכn fכ Kadiכjen insay kכdivaskyul εn sεribrovaskul hεlth mεntenans.


Klinik Stɔdi: Sɔm smɔl smɔl klinik stɔdi dɛn dɔn du fɔs asɛsmɛnt bak fɔ di sef ɛn ɛfifikɛshɔn fɔ Cardiogen. Insay stεdi dεm we dεn tכk bכt pasεn dεm wit aritmia, dεn fכnshכn se afta tritmεnt wit Cardiogen, di pasεnshכn dεm in aritmia sεmtεm dεm impruv bכku, εn no siriכs advεs rεakshכn nכ apin, we sho in pכtεnshal aplikεshכn valyu insay di tritmεnt fכ aritmia. Insay klinik stεdi dεm pan mayokardial infarkshכn pasεnshכn dεm, dεn bin si se pasεnshכn dεm we dεn trit wit Cardiogen bin gεt bεtε kadyak fכnshכn rεkכvεshכn pas di kכntrol grup, we kכnfכm in tεrapi ifekt pan mayokardial infarkshכn mכr.  




Dɔn


Fɔ sɔmtin, Kadiɔjen de ple impɔtant pat fɔ mek di at ɛn di blɔd gɛt wɛlbɔdi. Tru in multifaceted ifekt dεm pan di hat εn bכdi vεsul dεm, i de ol signifyant aplikεshכn pכtεnshal in כl tu di klinik tritmεnt εn de hεlth mεntenans.




Sos dɛn we dɛn pul


[1] Martínez-Iglesias O, Naidoo V, K ɛ r ɛra I, ɛn ɔda pipul dɛn. Natural Bioproducts wit Epigenetic Properties fכ Trit Kadivaskyul Dizכrd[J]. Jin, 2025,16(5}, 1999.

ATIKUL-NƆMBA = {566). DOI:10.3390/jin dɛn16050566.


[2] Lin X, P eng P, Cheng L, ɛn ɔda pipul dɛn. wan nεchכral kכmpawnd indyuz kadyojεnik difrεns fכ εndojεnik MSC dεm fכ ripa infarkted hat[J]. Difrɛns, 2012,83(1):1-9.DOI:10.1016/j.diff.2011.09.001.


[3] Cheng L, Chen H, Yao X, ɛn ɔda pipul dɛn. wan mεdi we kכmכt frכm plant fכ ripa di at we infakt[J]. Plos Wan, 2009,4(2):e4461.DOI:10.1371/jɔnal.pon.0004461.


Prodak we de fɔ yuz fɔ risach nɔmɔ:

Kadiɔjen-20mg

 Kontakt Wi Naw fɔ Wan Quote!
Cocer Peptides TM na sɔs saplay we yu kin trɔst ɔltɛm.

KWƐK LINK DƐN

KONTAKT WI
  WatsAp fɔ yu
+85269048891 na di kɔmni
  Sayn we yu de yuz
+85269048891 na di kɔmni
  Tɛligram we dɛn kɔl
@CocerService we de wok fɔ di kɔmni
  Imel fɔ yu
  Di De dɛn fɔ Ship
Mɔnde-Satde /Ɛkspɛkt Sɔnde
Ɔda dɛn we dɛn put ɛn pe afta 12 PM PST, dɛn kin ship dɛn di nɛks biznɛs de
Kopirayt © 2025 Cocer Peptides Co., Ltd. Ɔl di rayt dɛn de fɔ yuz. Sitemap fɔ di sayt | Prayvesi Polisi